Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company
focused on discovering, developing, and commercializing small molecule
drugs to treat severe medical conditions, today announced that the
Department of Defense (DoD) has recommended STA-9584, a novel vascular
disrupting agent (VDA) currently in pre-clinical development at Synta,
...
read more